Fragment-Based Interrogation of the 14–3–3/TAZ Protein–Protein Interaction-Reference-Cited by-同舟云学术

Fragment-Based Interrogation of the 14–3–3/TAZ Protein–Protein Interaction

Published:2024-08-22 Issue:17 Volume:63 Page:2196-2206
ISSN:0006-2960
Container-title:Biochemistry
language:en
Short-container-title:Biochemistry

Author:

Andlovic Blaž¹²,Valenti Dario²³,Centorrino Federica²,Picarazzi Francesca⁴,Hristeva Stanimira³,Hiltmann Malgorzata¹,Wolf Alexander¹,Cantrelle François-Xavier⁵⁶^ORCID,Mori Mattia⁴^ORCID,Landrieu Isabelle⁵⁶^ORCID,Levy Laura M.³,Klebl Bert¹,Tzalis Dimitrios³,Genski Thorsten³,Eickhoff Jan¹,Ottmann Christian²^ORCID

Affiliation:

1. Lead Discovery Center GmbH, Otto-Hahn-Str. 15, 44227 Dortmund, Germany

2. Laboratory of Chemical Biology, Department of Biomedical Engineering and Institute for Complex Molecular Systems, Eindhoven University of Technology, Den Dolech 2, 5612 AZ Eindhoven, The Netherlands

3. Taros Chemicals GmbH & Co. KG, Emil-Figge-Straße 76a, 44227 Dortmund, Germany

4. Department of Biotechnology, Chemistry and Pharmacy, University of Siena, Via Aldo Moro 2, 53100 Siena, Italy

5. CNRS EMR9002 Integrative Structural Biology, University of Lille, F-59000 Lille, France

6. University of Lille, Inserm, Institut Pasteur de Lille, U1167─RID-AGE─Risk Factors and Molecular Determinants of Aging-Related Diseases, F-59000 Lille, France

Funder

H2020 Marie Sklodowska-Curie Actions

Publisher

American Chemical Society (ACS)

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.biochem.4c00248

Reference80 articles.

1. Molecular complexity and fragment-based drug discovery: ten years on

2. Vemurafenib: the first drug approved for BRAF-mutant cancer

3. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets

4. Discovery and Pharmacological Characterization of JNJ-42756493 (Erdafitinib), a Functionally Selective Small-Molecule FGFR Family Inhibitor

5. Structure-Guided Blockade of CSF1R Kinase in Tenosynovial Giant-Cell Tumor